Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease.

Blasko I, Kemmler G, Jungwirth S, Wichart I, Krampla W, Weissgram S, Jellinger K, Tragl KH, Fischer P.

Am J Geriatr Psychiatry. 2010 Nov;18(11):973-82. doi: 10.1097/JGP.0b013e3181df48be.

PMID:
20808106
2.

Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.

Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P.

Neurobiol Aging. 2008 Jan;29(1):1-11. Epub 2006 Oct 19.

PMID:
17055615
3.

Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort.

Blasko I, Jungwirth S, Jellinger K, Kemmler G, Krampla W, Weissgram S, Wichart I, Tragl KH, Hinterhuber H, Fischer P.

J Psychiatr Res. 2008 Sep;42(11):946-55. Epub 2007 Dec 21.

PMID:
18155247
4.

Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors.

Blasko I, Kemmler G, Jungwirth S, Wichart I, Weissgram S, Jellinger K, Tragl KH, Fischer P.

J Neural Transm (Vienna). 2011 May;118(5):663-72. doi: 10.1007/s00702-011-0599-4. Epub 2011 Feb 23.

PMID:
21344239
5.

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG.

Arch Neurol. 2007 Mar;64(3):354-62. Erratum in: Arch Neurol. 2007 Sep;64(9):1246.

PMID:
17353377
6.

Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele.

Sun X, Chiu CC, Liebson E, Crivello NA, Wang L, Claunch J, Folstein M, Rosenberg I, Mwamburi DM, Peter I, Qiu WQ.

Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):238-44. doi: 10.1097/WAD.0b013e31819cb3ac.

7.

Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease.

Qiu WQ, Zhu H, Dean M, Liu Z, Vu L, Fan G, Li H, Mwamburi M, Steffens DC, Au R.

Int J Geriatr Psychiatry. 2016 Mar;31(3):316-22. doi: 10.1002/gps.4339. Epub 2015 Aug 6.

8.

Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly.

Qiu WQ, Sun X, Selkoe DJ, Mwamburi DM, Huang T, Bhadela R, Bergethon P, Scott TM, Summergrad P, Wang L, Rosenberg I, Folstein M.

Int J Geriatr Psychiatry. 2007 Jun;22(6):536-42.

PMID:
17096467
9.

Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.

Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST.

Neurology. 2008 May 6;70(19):1664-71. doi: 10.1212/01.wnl.0000306696.82017.66. Epub 2008 Apr 9.

10.

The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.

Fei M, Jianghua W, Rujuan M, Wei Z, Qian W.

J Neurol Sci. 2011 Jun 15;305(1-2):92-6. doi: 10.1016/j.jns.2011.03.005. Epub 2011 Mar 26.

PMID:
21440911
11.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
12.

Plasma beta amyloid level and depression in older adults.

Metti AL, Cauley JA, Newman AB, Ayonayon HN, Barry LC, Kuller LM, Satterfield S, Simonsick EM, Yaffe K.

J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):74-9. doi: 10.1093/gerona/gls093. Epub 2012 Apr 12.

13.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
14.

Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.

Seppälä TT, Herukka SK, Hänninen T, Tervo S, Hallikainen M, Soininen H, Pirttilä T.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1123-7. doi: 10.1136/jnnp.2010.205757. Epub 2010 May 16.

15.

Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.

Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM.

Neurology. 2006 Jan 10;66(1):23-9.

PMID:
16401840
16.

Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.

Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV.

J Alzheimers Dis. 2011;24(1):25-34. doi: 10.3233/JAD-2010-101248.

17.

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM.

Arch Neurol. 2000 Jan;57(1):100-5.

PMID:
10634455
18.

Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.

Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM.

Neurobiol Aging. 2011 Aug;32(8):1372-8. doi: 10.1016/j.neurobiolaging.2009.08.006. Epub 2009 Sep 11.

PMID:
19748159
19.

Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.

Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, Lee DH, Ye BS, Kim JH, Kim EJ, Park KH, Han HJ, Jeong JH, Choi SH, Park SA.

J Alzheimers Dis. 2015;48(4):1043-50. doi: 10.3233/JAD-143018.

PMID:
26444752
20.

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.

Arch Neurol. 2002 Nov;59(11):1729-34.

PMID:
12433260

Supplemental Content

Support Center